PSMA-targeting compounds and uses thereof
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
1. A compound having the structure:
wherein:
Z is tetrazole or CO 2 Q;
each Q is independently selected from hydrogen or a protecting group;
a is 1, 2, 3, or 4;
R is each independently H or C 1 -C 4 alkyl;
Ch is a metal chelating moiety optionally including a chelated metal, wherein Ch optionally includes any additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—;
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
V is —C(O)—, —NRC(O)—, —NRC(S)—, or —OC(O)—;
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
p is 1, 2, or 3, and when p is 2 or 3, each R 1 may be the same or different;
R 1 is H, C 1 -C 6 alkyl, C 2 -C 12 aryl, or C 4 -C 16 alkylaryl;
R 2 and R 3 are independently H, CO 2 H, or CO 2 R 4 , wherein R 4 is a C 1 -C 6 alkyl, C 2 -C 12 aryl, or C 4 -C 16 alkylaryl, wherein when one of R 2 and R 3 is CO 2 H or CO 2 R 4 , the other is H, and when p is 0, one of R 2 and R 3 is CO 2 R 4 , and the other is H.
2. The compound of claim 1 , wherein the compound has the structure:
3. The compound of claim 1 , wherein:
Z is CO 2 Q;
each Q is hydrogen;
R is H;
a is 4;
m is 6;
n is 3;
p is 2;
R 1 is C 2 -C 12 aryl, wherein the aryl may be substituted or unsubstituted and R 1 may be the same or different;
R 2 is CO 2 H;
R 3 is H;
W is —NRC(O)—, wherein R is H;
V is —C(O)—; and
Ch includes any additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound.
4. The compound of claim 3 , wherein R 1 is phenyl or a substituted phenyl.
5. The compound of claim 4 , wherein R 1 is a phenyl substituted at 1, 2, 3, or 4 positions with a substituent group selected from the group consisting of halogen, cyano, hydroxyl, nitro, azido, amino, alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aminoalkyl, carbocyclic aryl, arylalkyl, arylalkoxy, and a saturated, unsaturated, or aromatic heterocyclic group, may be further substituted.
6. The compound of claim 5 , wherein R 1 is a phenyl substituted with a halogen and a hydroxyl.
7. The compound of claim 1 , wherein the additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound comprises an alkyl, aryl, combination of alkyl and aryl, or alkyl and aryl groups having heteroatoms.
8. The compound of claim 7 , wherein the additional atoms or linkers necessary to attach the metal chelating moiety to the rest of the compound comprises an alkyl, wherein the alkyl may be substituted or unsubstituted.
9. The compound of claim 1 , wherein Ch comprises a structure selected from the group consisting of:
10. The compound of claim 1 , wherein Ch 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
11. The compound of claim 1 , wherein the compound is selected from the group consisting of:
12. The compound of claim 1 , wherein Ch includes a chelated metal and the chelated metal comprises a radioactive isotope.
13. The compound of claim 12 , wherein the radioactive isotope is Tc-99m, In-111, Ga-67, Ga-68, Y-86, Y-90, Lu-177, Re-186, Re-188, Cu-64, Cu-67, Co-55, Co-57, Sc-47, Ac-225, Bi-213, Bi-212, Pb-212, Sm-153, Ho-166, or Dy-166.
14. The compound of claim 13 , wherein the radioactive isotope is Ga-68 or Lu-177.
15. A method for imaging one or more prostate-specific membrane antigen (PSMA) tumors, or cells the method comprising contacting the one or more tumors, or cells, with an effective amount of a compound of claim 1 , and pharmaceutically acceptable salts thereof, and making an image.
16. The method of claim 15 , wherein the imaging comprises positron emission tomography (PET).
17. The method of claim 15 , wherein the one or more PSMA-expressing tumors or cells is selected from the group consisting of a prostate tumor or cell, a metastasized prostate tumor or cell, a lung tumor or cell, a renal tumor or cell, a glioblastoma, a pancreatic tumor or cell, a bladder tumor or cell, a sarcoma, a melanoma, a breast tumor or cell, a colon tumor or cell, a germ cell, a pheochromocytoma, an esophageal tumor or cell, a stomach tumor or cell, and combinations thereof.
18. A method for treating a tumor comprising administering a therapeutically effective amount of a compound of claim 1 , where the compound includes a therapeutically effective radioisotope.
19. A kit comprising a compound of claim 1 .